ATE456953T1 - Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga - Google Patents

Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga

Info

Publication number
ATE456953T1
ATE456953T1 AT06736552T AT06736552T ATE456953T1 AT E456953 T1 ATE456953 T1 AT E456953T1 AT 06736552 T AT06736552 T AT 06736552T AT 06736552 T AT06736552 T AT 06736552T AT E456953 T1 ATE456953 T1 AT E456953T1
Authority
AT
Austria
Prior art keywords
pyrimethamine
analogs
treatment
lateral sclerosis
amyotrophic lateral
Prior art date
Application number
AT06736552T
Other languages
English (en)
Inventor
Sean Scott
Daniel Benjamin
Original Assignee
Alsgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alsgen Inc filed Critical Alsgen Inc
Application granted granted Critical
Publication of ATE456953T1 publication Critical patent/ATE456953T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06736552T 2005-03-04 2006-03-01 Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga ATE456953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65850505P 2005-03-04 2005-03-04
PCT/US2006/007257 WO2006096405A2 (en) 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues

Publications (1)

Publication Number Publication Date
ATE456953T1 true ATE456953T1 (de) 2010-02-15

Family

ID=36953835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736552T ATE456953T1 (de) 2005-03-04 2006-03-01 Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga

Country Status (10)

Country Link
US (1) US20060211645A1 (de)
EP (1) EP1917017B1 (de)
JP (1) JP2008531710A (de)
CN (1) CN101184493A (de)
AT (1) ATE456953T1 (de)
AU (1) AU2006220919A1 (de)
CA (1) CA2600067A1 (de)
DE (1) DE602006012115D1 (de)
ES (1) ES2340708T3 (de)
WO (1) WO2006096405A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101232888A (zh) * 2005-03-04 2008-07-30 阿尔斯根公司 用炔诺酮及其类似物治疗肌萎缩性侧索硬化
US20060211673A1 (en) * 2005-03-04 2006-09-21 Alsgen, Llc Modulation of neurodegenerative diseases through the estrogen receptor
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2008046056A1 (en) * 2006-10-13 2008-04-17 Welldoc Communications, Inc. Reduction of nonspecific binding in nucleic acid assays and nucleic acid synthesis reactions
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
KR20100135711A (ko) 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
WO2010132999A1 (en) * 2009-05-21 2010-11-25 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
CA2833771C (en) * 2011-06-10 2021-08-03 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
WO2021096199A1 (ko) * 2019-11-11 2021-05-20 에스케이케미칼 주식회사 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US7442629B2 (en) * 2004-09-24 2008-10-28 President & Fellows Of Harvard College Femtosecond laser-induced formation of submicrometer spikes on a semiconductor substrate
WO2003045923A1 (en) * 2001-11-28 2003-06-05 Btg International Ltd. Preventives or remedies for alzheimer’s disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
DK1483247T3 (da) * 2002-03-13 2009-08-17 Euro Celtique Sa Arylsubstituerede pyrimidiner og anvendelsen deraf
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN101232888A (zh) * 2005-03-04 2008-07-30 阿尔斯根公司 用炔诺酮及其类似物治疗肌萎缩性侧索硬化
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2006096405A3 (en) 2007-05-18
EP1917017B1 (de) 2010-02-03
CN101184493A (zh) 2008-05-21
AU2006220919A1 (en) 2006-09-14
DE602006012115D1 (de) 2010-03-25
CA2600067A1 (en) 2006-09-14
WO2006096405A2 (en) 2006-09-14
ES2340708T3 (es) 2010-06-08
WO2006096405A8 (en) 2008-04-10
JP2008531710A (ja) 2008-08-14
US20060211645A1 (en) 2006-09-21
EP1917017A2 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
TW200531689A (en) Therapeutic agents
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
ECSP066336A (es) Derivados de 3-amino croman y 2-amino tetralin
WO2008067389A3 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
TW200611695A (en) Pyrrolopyridine derivatives
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE433966T1 (de) Methylendipiperidinderivate
TW200635903A (en) Therapeutic agents
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
TW200633986A (en) Therapeutic agents
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
EA200702253A1 (ru) Фармацевтическая композиция

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties